Get the Stockscreener App
291.55
0.18%
-0.52
After Hours:
291.55
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $291.55, with a volume of 1.37M.
It is down -0.18% in the last 24 hours and down -0.20% over the past month.
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$292.07
Open:
$295.52
24h Volume:
1.37M
Relative Volume:
0.77
Market Cap:
$56.51B
Revenue:
$310.23B
Net Income/Loss:
$1.69B
P/E Ratio:
33.82
EPS:
8.62
Net Cash Flow:
$3.58B
1W Performance:
-0.63%
1M Performance:
-0.20%
6M Performance:
+16.60%
1Y Performance:
+26.48%
1-Day Range:
$288.20
$296.70
1-Week Range:
$285.98
$296.70
52-Week Range:
$218.65
$309.35
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
291.55 | 56.87B | 310.23B | 1.69B | 3.58B | 8.62 |
|
MCK
Mckesson Corporation
|
714.88 | 90.05B | 359.05B | 3.30B | 5.23B | 25.83 |
|
CAH
Cardinal Health Inc
|
155.48 | 36.92B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
70.57 | 9.21B | 12.50B | 314.00M | 421.00M | 2.44 |
|
YI
111 Inc Adr
|
8.08 | 69.56M | 2.05B | -45.99M | 5.54M | -0.5634 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Wells Fargo Upgrades Cencora (COR) Stock to Overweight, Lifts PT - Insider Monkey
Cardinal Health stock, Cencora stock upgraded at Wells Fargo - Seeking Alpha
Wells Fargo Upgrades Cencora (COR) - Nasdaq
Wells Fargo upgrades Cencora stock rating, raises price target to $337 - Investing.com
Wells Fargo Upgrades Cencora (COR) with Raised Price Target | COR Stock News - GuruFocus
Cencora (COR) Receives Upgrade as Analysts Set New Price Target - GuruFocus
Wells Fargo Elevates Cencora (COR) to Overweight with Raised Price Target | COR Stock News - GuruFocus
Insider Sell Alert: Lazarus Krikorian Sells 3,000 Shares of Cencora Inc (COR) - GuruFocus
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Cencora, Inc. Declares Quarterly Cash Dividend, Payable on June 2, 2025 - marketscreener.com
Here's Why You Should Add Cencora Stock to Your Portfolio Now - MSN
Nephron Research Adjusts Cencora Price Target to $335 From $325 - marketscreener.com
Cencora, Inc. (COR) Announces Board Changes: New Appointment and Resignation - GuruFocus
Cencora Announces New Board Appointment Amid Recent Resignation - TipRanks
Cencora Appoints Lori J. Ryerkerk To Board - citybiz
Cencora appoints new board member to boost growth By Investing.com - Investing.com India
Cencora Elects Lori J. Ryerkerk to Its Board of Directors | COR Stock News - GuruFocus
Cencora appoints new board member to boost growth - Investing.com
Cencora Elects Lori J. Ryerkerk To Its Board Of Directors - marketscreener.com
Global Supply Chain Expert and Former Fortune 500 CEO Lori Ryerkerk Strengthens Cencora Board - Stock Titan
Baird Adjusts Price Target on Cencora to $351 From $350, Maintains Outperform Rating - marketscreener.com
Beat the Market the Zacks Way: GE Aerospace, Monster Beverage, Cencora in Focus - MSN
Cencora Completes €1 Billion Senior Notes Sale - TipRanks
Insider Sell: Steven Collis Sells Shares of Cencora Inc (COR) - GuruFocus
Cencora, Inc. (COR) Announces €1 Billion Senior Notes Offering - GuruFocus
Cencora Enters €1 Billion Senior Notes Agreement - TipRanks
Robust Results Lifted Cencora (COR) Amid Upgraded Outlook - Insider Monkey
Jim Cramer Highlights Cencora (COR) “Knocked It Out of The Park” - Insider Monkey
8 Stocks on Jim Cramer’s Radar Recently - Insider Monkey
Cencora, Inc. concludes securities offering without stabilisation action By Investing.com - Investing.com Nigeria
Insider Sell Alert: Lon Greenberg Sells 3,000 Shares of Cencora Inc (COR) - GuruFocus
Cencora Director Sells Stock in Major Transaction - TipRanks
Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs - Seeking Alpha
Cencora, Inc. concludes securities offering without stabilisation action - Investing.com
Cencora, Inc. announces potential market stabilization measures By Investing.com - Investing.com South Africa
Cencora Reports Strong Q2 2025 Results, Raises Outlook - MSN
Cencora Files For Two-Part Senior Notes Offering Size Not Disclosed- SEC Filing - marketscreener.com
Cencora, Inc. announces potential market stabilization measures - Investing.com
Cencora increases FY2025 EPS guidance to $15.70-$15.95 amid specialty growth - MSN
Cencora's (NYSE:COR) Soft Earnings Don't Show The Whole Picture - Yahoo Finance
Do Wall Street Analysts Like Cencora Stock? - MSN
Transcript : Cencora, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 11 - marketscreener.com
JPMorgan Adjusts Price Target on Cencora to $326 From $301, Maintains Overweight Rating - marketscreener.com
Beat the Market the Zacks Way: Limbach, Stride, Cencora in Focus - Yahoo Finance
Is It Smart To Buy Cencora, Inc. (NYSE:COR) Before It Goes Ex-Dividend? - Yahoo Finance
Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):